Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07221799 · ClinicalTrials.gov registry record · Phase 1
OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis
A Phase 1 study, sponsored by University of Maryland, Baltimore.
- Not yet
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT07221799 is a Phase 1 study that has not yet begun recruiting, run by University of Maryland, Baltimore. The registered enrollment target is 10 participants.
The verdict
NCT07221799, a Phase 1 study, has not yet begun recruiting, sponsored by University of Maryland, Baltimore.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is an early phase safety evaluation of the use of oral extended release (OER) glibenclamide, which is otherwise known as glyburide, for use as a treatment for neurologic pain in people with multiple sclerosis. Patients will receive medication to assess safety and tolerability.
Interventions
- DRUG Placebo
- DRUG glibenclamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2026-09-01 |
| Est. Completion | 2029-09-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07221799
The ClinicalTrials.gov registry entry for NCT07221799 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07221799 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07221799 about?
NCT07221799 is a clinical study titled "OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis". This is an early phase safety evaluation of the use of oral extended release (OER) glibenclamide, which is otherwise known as glyburide, for use as a treatment for neurologic pain in people with multiple sclerosis. Patients will receive medication to assess safety and tolerability.
What is the current status of trial NCT07221799?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2026-09-01. Estimated completion is 2029-09-01.
What interventions are being tested in trial NCT07221799?
The interventions under investigation include: Placebo (DRUG), glibenclamide (DRUG).
Who is sponsoring clinical trial NCT07221799?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.